We found that the sensitivity and specificity of serum Smad4 concentration to distinguish NSCLC from healthy individuals were 91.56% and 61.56% while the sensitivity and specificity of serum Smad4 concentration to distinguish NSCLC from benign lung disease were 84.55% and 60.36%. This evidence concerns the gene SMAD4 and non-small cell lung carcinoma.